Systemic rosiglitazone plus NECTIN4-CAR T cells also improved tumor growth inhibition in HT1197 tumor xenografts (Fig. 4k), without affecting body weight (Fig. 4l). The gene discussed is NECTIN4; the disease is neoplasm.